Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • Equities
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Macro Notification
  • Management
  • Market Summary
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Mining
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week

Benzinga Neuro

2693 posts
Group By Ticker
Sort By
Newest | Oldest
Read More
2 minute read
  • Analyst Color
  • Analyst Ratings
  • General
  • Markets
  • News

Cramer Calls Palantir A ‘Buy, Buy, Buy’ Despite Controversial CEO, Karp’s ‘Insanity Is Growing’ On Him

By Benzinga Neuro
February 7, 4:44 AM
Despite the controversy surrounding Palantir's CEO, Alex Karp, Cramer's endorsement is a significant vote of confidence in the company.

PLTR

Read More
2 minute read
  • Government
  • Legal
  • Media
  • News
  • Regulations
  • Tech
  • Top Stories

California Judge Urges GM’s Cruise To Raise Settlement Offer By 1.5x In Robotaxi Accident Case

By Benzinga Neuro
February 7, 4:36 AM
Cruise last month had proposed a $75,000 settlement to address the ongoing investigation into the accident.

GM

Read More
2 minute read
  • News
  • Social Media

X Rival, Jack Dorsey-Backed Bluesky Drops Invite-Only Model, Opens Doors To All Users

By Benzinga Neuro
February 7, 3:28 AM
In a recent development, Bluesky, the decentralized social media platform, has decided to remove its invite-only sign-up system and open its doors to all interested users.

META

Read More
2 minute read
  • General
  • News
  • Tech

Salesforce Executive Threatens To Withhold Stock Grants, Bonuses If Employees Fail To Meet Training Goals: Report

By Benzinga Neuro
February 7, 1:15 AM
The company's president and chief engineering officer, Srini Tallapragada, sent an email to his direct reports, stating that those who do not achieve the "ranger" rank on the company's internal training platform could miss out on stock grants and bonus payments.

CRM

Read More
2 minute read
  • Biotech
  • Global
  • Health Care
  • News
  • Tech

Amazon Implements Major Job Cuts In One Medical And Pharmacy Units To Save $100M

By Benzinga Neuro
February 6, 11:46 PM
Amazon has announced that it will lay off hundreds of employees at its One Medical and Pharmacy units as part of a major cost-cutting initiative.

AMZN

Read More
2 minute read
  • Uncategorized

Snap, Alibaba, Ford, Disney, Tesla: Why These 5 Stocks Are On Investors’ Radars Today

By Benzinga Neuro
February 6, 11:02 PM
U.S. stocks showed positive momentum today, with the Dow Jones index climbing over 140 points.

BABA

Read More
2 minute read
  • Equities
  • ETFs
  • Markets
  • News

Cathie Wood’s Ark Invest Lost More Than $14B In Wealth Over Past Decade: Report

By Benzinga Neuro
February 6, 10:17 PM
The much-hyped investment firm Ark Invest, led by Cathie Wood, has reportedly seen a massive erosion of wealth over the past ten years, amounting to a staggering $14.3 billion.

ARKK

Read More
2 minute read
  • Equities
  • Markets
  • News
  • Tech

Long-Time Tesla Investor Says Elon Musk’s Alleged Drug Use, Party Culture Could Be Distracting Investors From EV Giant’s Deeper Issues

By Benzinga Neuro
February 6, 9:55 PM
Elon Musk's alleged partying and drug use with Tesla board members might be causing discomfort among investors, but these issues are overshadowing more significant execution problems at the company, according to a long-time Tesla shareholder.

TSLA

Read More
2 minute read
  • Equities
  • General
  • Markets
  • News

Eli Lilly Soars On Diabetes And Obesity Drug Boom, Projects 20% Revenue Increase In 2024

By Benzinga Neuro
February 6, 10:15 AM
This surge is attributed to the popularity of Lilly's new diabetes drug, Mounjaro, and its anti-obesity medication, Zepbound.

LLY

Read More
2 minute read
  • Equities
  • General
  • Markets
  • News
  • Top Stories

Guess Who’s Back? Adam Neumann Reportedly Eyes To Purchase WeWork As Bankruptcy Looms Large

By Benzinga Neuro
February 6, 9:55 AM
Neumann and Third Point have been reportedly attempting to acquire crucial information from WeWork since December to formulate a bid.

WEWKQ

Posts pagination

Previous 1 … 105 106 107 … 270 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service